Related Experiment Video
Updated: Jul 2, 2026

Intravitreous Injection for Establishing Ocular Diseases Model
Published on: October 1, 2007
Macular Toxicity Following Intravitreal Clindamycin: A Case Report and Literature Review
Sahba Fekri1,2, Shahriyar Shafa3, Amin Zand3
1Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Purpose:
To present a case of retinal toxicity following intravitreal clindamycin injection in a patient with toxoplasma retinochoroiditis and to review the relevant literature.
Methods:
A single case was evaluated, documented, and described.
Results:
A 41-year-old woman with reactivated Toxoplasma retinochoroiditis in her right eye received intravitreal clindamycin (1 mg/0.1 mL) and dexamethasone (0.4 mg/0.1 mL). Regrettably, her visual acuity declined to hand motion one day post-injection. Fundus examination revealed extensive macular necrosis with retinal vascular occlusion, suggestive of retinal infarction. Despite high dose systemic steroid therapy, her condition progressed to macular atrophy and severe vision loss.
Conclusion:
Macular infarction is a rare but devastating complication of intravitreal clindamycin injection. This risk should always be considered when intravitreal therapy is planned for the treatment of ocular toxoplasmosis.
More Related Videos
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Cardiomyopathy II: Dilated Cardiomyopathy
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Yellow Fever
Diabetic Retinopathy

